Trial Profile
A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Hafnium oxide (Primary)
- Indications Soft tissue sarcoma
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms Act.in.sarc
- Sponsors Nanobiotix; PharmaEngine
- 28 Sep 2022 Final results of Safety and Health-Related Quality of LIfe of the Phase 2/3 Act.In.Sarc Study published in the International Journal of Radiation Oncology, Biology, Physics
- 13 Sep 2022 Results of an analysis assessing feasibility and safety from phase I trials: NCT02379845, NCT01946867, NCT02721056, NCT03589339, NCT04484909, NCT04615013 and NCT02805894 presented at the 47th European Society for Medical Oncology Congress
- 06 Oct 2021 According to a Nanobiotix media release, data will be presented at the 2021 Annual Meeting of the American Society for Radiation Oncology (ASTRO).